{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:06:30Z","timestamp":1782331590697,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630090"],"award-info":[{"award-number":["81630090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81822045"],"award-info":[{"award-number":["81822045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic\/Technology Research Leader","doi-asserted-by":"publisher","award":["20XD1420300"],"award-info":[{"award-number":["20XD1420300"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Clinical Research Center for Infectious Disease (HIV\/AIDS)","award":["20MC1920100"],"award-info":[{"award-number":["20MC1920100"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Acquired immune deficiency syndrome (AIDS) has prevailed over the last 30 years. Although highly active antiretroviral therapy (HAART) has decreased mortality and efficiently controlled the progression of disease, no vaccine or curative drugs have been approved until now. A viral inactivator is expected to inactivate cell-free virions in the absence of target cells. Previously, we identified a gp120-binding protein, mD1.22, which can inactivate laboratory-adapted HIV-1. In this study, we have found that the gp41 N-terminal heptad repeat (NHR)-binding antibody D5 single-chain variable fragment (scFv) alone cannot inactivate HIV-1 at the high concentration tested. However, D5 scFv in the combination could enhance inactivation activity of mD1.22 against divergent HIV-1 strains, including HIV-1 laboratory-adapted strains, primary HIV-1 isolates, T20- and AZT-resistant strains, and LRA-reactivated virions. Combining mD1.22 and D5 scFv exhibited synergistic effect on inhibition of infection by divergent HIV-1 strains. These results suggest good potential to develop the strategy of combining a gp120-binding protein and a gp41-binding antibody for the treatment of HIV-1 infection.<\/jats:p>","DOI":"10.3390\/molecules26071964","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:24:33Z","timestamp":1617186273000},"page":"1964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection"],"prefix":"10.3390","volume":"26","author":[{"given":"Xinling","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Cao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlei","family":"Ying","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-0391","authenticated-orcid":false,"given":"Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-7135","authenticated-orcid":false,"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"},{"name":"Key Laboratory of Reproduction Regulation of National Population and Family Planning Commission, The Shanghai Institute of Planned Parenthood Research, Institute of Reproduction and Development, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00003495-199957030-00006","article-title":"Managing resistance to anti-HIV drugs: An important consideration for effective disease management","volume":"57","author":"Vandamme","year":"1999","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.bbamem.2012.07.020","article-title":"HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain","volume":"1818","author":"Lu","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/QAD.0000000000000255","article-title":"Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides\u2019 anti-HIV activity","volume":"28","author":"Zheng","year":"2014","journal-title":"AIDS"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Su, S., Rasquinha, G., Du, L., Wang, Q., Xu, W., Li, W., Lu, L., and Jiang, S. (2019). A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules, 24.","DOI":"10.3390\/molecules24061134"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nsb1295-1075","article-title":"A Trimeric Structural Domain of the Hiv-1 Transmembrane Glycoprotein","volume":"2","author":"Lu","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/07391102.1997.10508958","article-title":"A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein","volume":"15","author":"Lu","year":"1997","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000367","article-title":"Engineering antibody-like inhibitors to prevent and treat HIV-1 infection","volume":"12","author":"Gardner","year":"2017","journal-title":"Curr. Opin. Hiv. Aids"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/331082a0","article-title":"A soluble form of CD4 (T4) protein inhibits AIDS virus infection","volume":"331","author":"Deen","year":"1988","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17121","DOI":"10.1073\/pnas.0805297105","article-title":"Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1128\/JVI.02566-13","article-title":"Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-9-104","article-title":"A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains","volume":"9","author":"Lu","year":"2012","journal-title":"Retrovirology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.00376-10","article-title":"Potent strategy to inhibit HIV-1 by binding both gp120 and gp41","volume":"55","author":"Kagiampakis","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Haim, H., Si, Z., Madani, N., Wang, L., Courter, J.R., Princiotto, A., Kassa, A., DeGrace, M., McGee-Estrada, K., and Mefford, M. (2009). Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000360"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1038\/emi.2017.46","article-title":"HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions","volume":"6","author":"Qi","year":"2017","journal-title":"Emerg. Microbes Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3389\/fmicb.2020.01063","article-title":"Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry into Cells","volume":"11","author":"Su","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in Antibody Design","volume":"17","author":"Tiller","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.0506927102","article-title":"A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope","volume":"102","author":"Miller","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1110\/ps.038273.108","article-title":"Characterization of the steric defense of the HIV-1 gp41 N-trimer region","volume":"17","author":"Eckert","year":"2008","journal-title":"Protein Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wei, D.G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J.P., and Stepan, G. (2014). Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004071"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune-Deficiency Syndrome (Aids)","volume":"220","author":"Barresinoussi","year":"1983","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.coph.2020.09.017","article-title":"Recent discoveries in HIV-1 reverse transcriptase inhibitors","volume":"54","author":"Gu","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","article-title":"Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance","volume":"48","author":"Bandera","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/aid.1995.11.533","article-title":"Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates","volume":"11","author":"Allaway","year":"1995","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1128\/JVI.72.3.1876-1885.1998","article-title":"Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage","volume":"72","author":"Trkola","year":"1998","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1128\/JVI.72.4.3475-3478.1998","article-title":"CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates","volume":"72","author":"Gauduin","year":"1998","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/AAC.48.2.423-429.2004","article-title":"Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542","volume":"48","author":"Jacobson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Su, S., Ma, Z., Hua, C., Li, W., Lu, L., and Jiang, S. (2017). Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. Molecules, 22.","DOI":"10.3390\/molecules22111996"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000000265","article-title":"Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs","volume":"67","author":"Xu","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/7\/1964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:33:15Z","timestamp":1760362395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/7\/1964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["molecules26071964"],"URL":"https:\/\/doi.org\/10.3390\/molecules26071964","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}